TY  - BOOK
AU  - Asch, Federico M
TI  - 1-Year Outcomes With Fourth-Generation Mitral Valve Transcatheter Edge-to-Edge Repair From the EXPAND G4 Study
SN  - 1936-8798
PY  - 2023///
KW  - *Cardiomyopathies
KW  - *Heart Failure
KW  - *Heart Valve Prosthesis Implantation
KW  - *Mitral Valve Insufficiency
KW  - Humans
KW  - Mitral Valve Insufficiency/dg [Diagnostic Imaging]
KW  - Mitral Valve Insufficiency/su [Surgery]
KW  - Mitral Valve/dg [Diagnostic Imaging]
KW  - Mitral Valve/su [Surgery]
KW  - Prospective Studies
KW  - Quality of Life
KW  - Treatment Outcome
KW  - MedStar Health Research Institute
KW  - Journal Article
KW  - Multicenter Study
N2  - BACKGROUND: The fourth-generation mitral transcatheter edge-to-edge repair (M-TEER) device introduced an improved clip deployment sequence, independent leaflet grasping, and 2 wider clip sizes to tailor the treatment of patients with mitral regurgitation (MR) for a broad range of anatomies. The 30-day safety and effectiveness of the fourth-generation M-TEER device were previously demonstrated; CONCLUSIONS: M-TEER with the fourth-generation M-TEER device was safe and effective at 1 year, with durable reductions in MR severity to <=1+ in more than 90% of patients and concomitant improvements in functional status and quality of life. Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved; METHODS: EXPAND G4 is an ongoing prospective, multicenter, international, single-arm study that enrolled subjects with primary and secondary MR. One-year outcomes included MR severity (echocardiographic core laboratory assessed), heart failure hospitalization, all-cause mortality, functional capacity (NYHA functional class), and quality of life (Kansas City Cardiomyopathy Questionnaire); OBJECTIVES: The aim of this study was to evaluate 1-year outcomes in a contemporary, real-world cohort of subjects treated with the MitraClip G4 system; RESULTS: A total of 1,164 subjects underwent M-TEER from 2020 to 2022. At 1 year, there was a durable reduction in MR to mild or less in 92.6% and to none or trace in 44.2% (P < 0.0001 vs baseline). Few subjects had major adverse events through 1 year (<2% for myocardial infarction, surgical reintervention, or single-leaflet device attachment). The 1-year Kaplan-Meier estimates for all-cause mortality and heart failure hospitalization were 12.3% and 16.9%. Significant improvements in functional capacity (NYHA functional class I or II in 82%; P < 0.0001 vs baseline) and quality of life (18.5-point Kansas City Cardiomyopathy Questionnaire overall summary score improvement; P < 0.0001) were observed
UR  - https://dx.doi.org/10.1016/j.jcin.2023.09.029
ER  -